Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Ann Childress, MD

Adjunct Faculty
UNLV and Touro University of Nevada
President
Center for Psychiatry and Behavioral Medicine, Inc
Adjunct Associate Professor
President
American Professional Society for ADHD and Related Disorders
Las Vegas, Nevada

Disclosures

Ann Childress, MD, has the following relevant financial relationships:
Consultant or advisor for: Aardvark; Adlon Therapeutics L.P.; Akili Interactive Labs, Inc.; Arbor Pharmaceuticals, Inc.; Attentive Therapeutics; Aytu (NEOS Therapeutics, Inc.); Cingulate; Corium International, Inc.; Ironshore Pharmaceuticals Inc.; Jazz Pharmaceuticals, Inc.; KemPharm; Lumos Pharma; Neurocentria; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Purdue Pharma L.P.; Sky; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Tris Pharma, Inc.; Tulex
Speaker or member of speakers bureau for: Corium International, Inc.; Ironshore Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.; Supernus Pharmaceuticals, Inc.; Tris Pharma, Inc.
Research funding from: Adlon Therapeutics L.P.; Akili Interactive Labs, Inc.; Allergan; Arbor Pharmaceuticals, Inc.; Cingulate; Emalex Biosciences (former); Ironshore Pharmaceuticals Inc.; KemPharm; Lumos Pharma; NEOS Therapeutics, Inc. (former); Neuocentria; Otsuka Pharmaceutical Co., Ltd.; Purdue Pharma L.P.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc. (Shire); Tris Pharma, Inc.
Contracted researcher for: Adlon Therapeutics L.P.; Akili Interactive Labs, Inc.; Allergan; Arbor Pharmaceuticals, Inc.; Cingulate; Emalex Biosciences; Ironshore Pharmaceuticals Inc.; KemPharm; Lumos Pharma; NEOS Therapeutics, Inc.; Neurocentria; Neurovance (former); Otsuka Pharmaceutical Co., Ltd.; Purdue Pharma L.P.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc. (Shire); Tris Pharma, Inc.
Other: Writing support: Arbor Pharmaceuticals, Inc.; Corium International, Inc.; NEOS Therapeutics, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Purdue Pharma L.P.; Rhodes Pharmaceuticals L.P.; Takeda Pharmaceuticals North America, Inc.

Gregory W. Mattingly, MD

Associate Clinical Professor
Washington University School of Medicine
President
Midwest Research Group
President-Elect
American Professional Society for ADHD and Related Disorders (APSARD)
St Louis, Missouri

Disclosures

Gregory W. Mattingly, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; Alkermes, Inc.; Axsome Therapeutics, Inc.; Biogen; Corium International, Inc.; Eisai Inc.; Ironshore Pharmaceuticals Inc.; Intra-Cellular Therapies, Inc.; Janssen Pharmaceuticals; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Redax; Roche; Sage Therapeutics, Inc.; Sirona; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.; Teva Pharmaceutical Industries Ltd.
Speaker or member of speakers bureau for: AbbVie Inc.; Alkermes, Inc.; Axsome Therapeutics, Inc.; Corium International, Inc.; Intra-Cellular Therapies, Inc.; Ironshore Pharmaceuticals Inc.; Janssen Pharmaceuticals; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.; Tris Pharma, Inc.
Research funding from: AbbVie Inc.; Akili Interactive Labs, Inc.; Alkermes, Inc.; Axsome Therapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Emalex Biosciences; Idorsia Pharmaceuticals, Ltd.; Janssen Pharmaceuticals; Karuna Therapeutics; Lumos Pharma; Medgenics; Neurocrine Biosciences, Inc.; NLS-1 Pharma AG; Otsuka Pharmaceutical Co., Ltd.; Redax; Relmada Therapeutics, Inc.; Roche; Sage Therapeutics, Inc.; Sirtsei Pharmaceuticals, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.; Teva Pharmaceuticals USA

Editors

Clinton W. Wright, PharmD, BCPP

Medical Education Director, Medscape, LLC

Disclosures

Clinton W. Wright, PharmD, BCPP, has no relevant financial relationships.

Megan Breuer, PhD

Medical Writer, Medscape, LLC

Disclosures

Megan Breuer, PhD, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME / CE

Assessing Practice Patterns in Care of Adults With ADHD

Authors: Ann Childress, MD; Gregory W. Mattingly, MD
CME / CE Released: 11/7/2023
Valid for credit through: 11/7/2024, 11:59 PM EST

Start Activity

Credits Available

Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

Nurses - 0.25 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)

Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)

IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit

You Are Eligible For
- Letter of Completion

Target Audience and Goal Statement

This activity is intended for psychiatrists, psychiatric nurse practitioners (NPs), primary care physicians (PCPs), nurses, pharmacists, and other clinicians who care for adult patients with ADHD.

The goal of this activity is to investigate clinician practice gaps and barriers in ADHD care while incorporating patient perspectives into the assessment of these gaps.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Role of nonstimulants in the treatment of adult ADHD
Self-assess learning needs related to
- Tailoring medication selection for adult patients with ADHD

Disclosures

Faculty

Ann Childress, MD

Adjunct Faculty
UNLV and Touro University of Nevada
President
Center for Psychiatry and Behavioral Medicine, Inc
Adjunct Associate Professor
President
American Professional Society for ADHD and Related Disorders
Las Vegas, Nevada

Disclosures

Ann Childress, MD, has the following relevant financial relationships:
Consultant or advisor for: Aardvark; Adlon Therapeutics L.P.; Akili Interactive Labs, Inc.; Arbor Pharmaceuticals, Inc.; Attentive Therapeutics; Aytu (NEOS Therapeutics, Inc.); Cingulate; Corium International, Inc.; Ironshore Pharmaceuticals Inc.; Jazz Pharmaceuticals, Inc.; KemPharm; Lumos Pharma; Neurocentria; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Purdue Pharma L.P.; Sky; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Tris Pharma, Inc.; Tulex
Speaker or member of speakers bureau for: Corium International, Inc.; Ironshore Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.; Supernus Pharmaceuticals, Inc.; Tris Pharma, Inc.
Research funding from: Adlon Therapeutics L.P.; Akili Interactive Labs, Inc.; Allergan; Arbor Pharmaceuticals, Inc.; Cingulate; Emalex Biosciences (former); Ironshore Pharmaceuticals Inc.; KemPharm; Lumos Pharma; NEOS Therapeutics, Inc. (former); Neuocentria; Otsuka Pharmaceutical Co., Ltd.; Purdue Pharma L.P.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc. (Shire); Tris Pharma, Inc.
Contracted researcher for: Adlon Therapeutics L.P.; Akili Interactive Labs, Inc.; Allergan; Arbor Pharmaceuticals, Inc.; Cingulate; Emalex Biosciences; Ironshore Pharmaceuticals Inc.; KemPharm; Lumos Pharma; NEOS Therapeutics, Inc.; Neurocentria; Neurovance (former); Otsuka Pharmaceutical Co., Ltd.; Purdue Pharma L.P.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc. (Shire); Tris Pharma, Inc.
Other: Writing support: Arbor Pharmaceuticals, Inc.; Corium International, Inc.; NEOS Therapeutics, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Purdue Pharma L.P.; Rhodes Pharmaceuticals L.P.; Takeda Pharmaceuticals North America, Inc.

Gregory W. Mattingly, MD

Associate Clinical Professor
Washington University School of Medicine
President
Midwest Research Group
President-Elect
American Professional Society for ADHD and Related Disorders (APSARD)
St Louis, Missouri

Disclosures

Gregory W. Mattingly, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; Alkermes, Inc.; Axsome Therapeutics, Inc.; Biogen; Corium International, Inc.; Eisai Inc.; Ironshore Pharmaceuticals Inc.; Intra-Cellular Therapies, Inc.; Janssen Pharmaceuticals; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Redax; Roche; Sage Therapeutics, Inc.; Sirona; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.; Teva Pharmaceutical Industries Ltd.
Speaker or member of speakers bureau for: AbbVie Inc.; Alkermes, Inc.; Axsome Therapeutics, Inc.; Corium International, Inc.; Intra-Cellular Therapies, Inc.; Ironshore Pharmaceuticals Inc.; Janssen Pharmaceuticals; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.; Tris Pharma, Inc.
Research funding from: AbbVie Inc.; Akili Interactive Labs, Inc.; Alkermes, Inc.; Axsome Therapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Emalex Biosciences; Idorsia Pharmaceuticals, Ltd.; Janssen Pharmaceuticals; Karuna Therapeutics; Lumos Pharma; Medgenics; Neurocrine Biosciences, Inc.; NLS-1 Pharma AG; Otsuka Pharmaceutical Co., Ltd.; Redax; Relmada Therapeutics, Inc.; Roche; Sage Therapeutics, Inc.; Sirtsei Pharmaceuticals, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.; Teva Pharmaceuticals USA

Editors

Clinton W. Wright, PharmD, BCPP

Medical Education Director, Medscape, LLC

Disclosures

Clinton W. Wright, PharmD, BCPP, has no relevant financial relationships.

Megan Breuer, PhD

Medical Writer, Medscape, LLC

Disclosures

Megan Breuer, PhD, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

Developed through a partnership between Medscape and American Professional Society of ADHD and Related Disorders (APSARD).

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

Contact This Provider

For Nurses

Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-23-374-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit(s)™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

ADHD Learning Destination

From Medscape Education Psychiatry & Mental Health

CME / CE

Assessing Practice Patterns in Care of Adults With ADHD

Authors: Ann Childress, MD; Gregory W. Mattingly, MDFaculty and Disclosures

CME / CE Released: 11/7/2023

Valid for credit through: 11/7/2024, 11:59 PM EST

processing....

Learning Feedback Questions

Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned.

Page 1 of 8

CME / CE Information

Print
Like Tweet

References

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Ann Childress, MD

Gregory W. Mattingly, MD

Editors

Clinton W. Wright, PharmD, BCPP

Megan Breuer, PhD

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

CME / CE

Assessing Practice Patterns in Care of Adults With ADHD

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Ann Childress, MD

Gregory W. Mattingly, MD

Editors

Clinton W. Wright, PharmD, BCPP

Megan Breuer, PhD

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Assessing Practice Patterns in Care of Adults With ADHD

Learning Feedback Questions